Previous Close | 1.3000 |
Open | 1.0000 |
Bid | 0.6700 |
Ask | 0.8000 |
Strike | 160.00 |
Expire Date | 2024-06-28 |
Day's Range | 0.6000 - 1.0000 |
Contract Range | N/A |
Volume | |
Open Interest | 363 |
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older Higher efficacy was observed in mRNA-1283 compared ...